tiprankstipranks
Trending News
More News >
Humacyte (HUMA)
NASDAQ:HUMA
US Market
Advertisement

Humacyte (HUMA) Stock Statistics & Valuation Metrics

Compare
1,312 Followers

Total Valuation

Humacyte has a market cap or net worth of $370.73M. The enterprise value is $306.67M.
Market Cap$370.73M
Enterprise Value$306.67M

Share Statistics

Humacyte has 155,118,820 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding155,118,820
Owned by Insiders4.86%
Owned by Institutions0.16%

Financial Efficiency

Humacyte’s return on equity (ROE) is 2.82 and return on invested capital (ROIC) is ―.
Return on Equity (ROE)2.82
Return on Assets (ROA)-1.08
Return on Invested Capital (ROIC)
Return on Capital Employed (ROCE)-0.97
Revenue Per Employee0.00
Profits Per Employee-682.11K
Employee Count218
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio8.40
Price to Fair Value-11.36
Price to FCF-3.54
Price to Operating Cash Flow-3.05
PEG Ratio>-0.01

Income Statement

In the last 12 months, Humacyte had revenue of 0.00 and earned -148.70M in profits. Earnings per share was -1.26.
Revenue0.00
Gross Profit0.00
Operating Income-114.40M
Pretax Income0.00
Net Income-148.70M
EBITDA-132.23M
Earnings Per Share (EPS)-1.26

Cash Flow

In the last 12 months, operating cash flow was -99.38M and capital expenditures -1.41M, giving a free cash flow of -100.78M billion.
Operating Cash Flow-99.38M
Free Cash Flow-100.78M
Free Cash Flow per Share-0.65

Dividends & Yields

Humacyte pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.27
52-Week Price Change-69.14%
50-Day Moving Average2.28
200-Day Moving Average3.49
Relative Strength Index (RSI)49.69
Average Volume (3m)3.50M

Important Dates

Humacyte upcoming earnings date is Aug 19, 2025, Before Open (Confirmed).
Last Earnings DateMay 13, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend Date

Financial Position

Humacyte as a current ratio of 2.40, with Debt / Equity ratio of 43.98%
Current Ratio2.40
Quick Ratio2.40
Debt to Market Cap0.11
Net Debt to EBITDA0.21
Interest Coverage Ratio-12.33

Taxes

In the past 12 months, Humacyte has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Humacyte EV to EBITDA ratio is -4.31, with an EV/FCF ratio of -5.72.
EV to Sales0.00
EV to EBITDA-4.31
EV to Free Cash Flow-5.72
EV to Operating Cash Flow-5.81

Balance Sheet

Humacyte has $62.85M in cash and marketable securities with $15.85M in debt, giving a net cash position of -$47.00M billion.
Cash & Marketable Securities$62.85M
Total Debt$15.85M
Net Cash-$47.00M
Net Cash Per Share-$0.30
Tangible Book Value Per Share-$0.44

Margins

Gross margin is 23.12%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin23.12%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Humacyte is $7.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.67
Price Target Upside216.94% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast-17.92%

Scores

Smart Score5
AI Score42
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis